Skip to Content
Get key facts and figures about chronic dry eye

Fluocinolone ophthalmic Pregnancy and Breastfeeding Warnings

Fluocinolone ophthalmic is also known as: Iluvien, Retisert, Yutiq

Medically reviewed on Jan 25, 2018

Fluocinolone ophthalmic Pregnancy Warnings

Animal reproduction studies have not been conducted. There are no adequate and well-controlled studies in pregnant women.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Use should be avoided.

US FDA pregnancy category: C

See references

Fluocinolone ophthalmic Breastfeeding Warnings

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments:
-The effects in the nursing infant are unknown.
-Systemic steroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. "Product Information. Retisert (fluocinolone ophthalmic)." Bausch and Lomb, Rochester, NY.

References for breastfeeding information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. "Product Information. Retisert (fluocinolone ophthalmic)." Bausch and Lomb, Rochester, NY.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide